Clinical trials: Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis (IPF)
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
This is a study for adults with a lung disease called idiopathic pulmonary fibrosis. The main purpose of this study is to look at how well deupirfenidone improves lung function and how safe it is for people with idiopathic…
- Trial name
- SURPASS-IPF (NCT07284602)
- Testing
- Deupirfenidone, Pirfenidone (PFD)
- Where
- 18 sites in United States, Canada
- Volunteers
- 1,100 people
- Sponsor
- PureTech
Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated…
- Trial name
- NCT05785624
- Testing
- Vixarelimab
- Where
- 114 sites in United States, Argentina and 17 more
- Volunteers
- 286 people
- Sponsor
- Genentech, Inc.
Idiopathic Pulmonary Fibrosis
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
- Trial name
- NCT05571059
- Testing
- Ifetroban Sodium
- Where
- 20 sites in United States
- Volunteers
- 128 people
- Sponsor
- Cumberland Pharmaceuticals
Idiopathic Pulmonary Fibrosis
OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study
Descriptive prospective non-interventional multicenter study based on newly collected data of Idiopathic Pulmonary Fibrosis patients followed-up for one year in secondary care settings (Pulmonology Services)
- Trial name
- NCT03386994
- Where
- 31 sites in Spain
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis…
- Trial name
- STARSCAPE (NCT04552899)
- Testing
- PRM-151 (Zinpentraxin Alfa)
- Where
- 360 sites in United States, Argentina and 33 more
- Volunteers
- 665 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
This is an open label multi-center program to allow patients in the US with IPF access to treatment with pirfenidone.
- Trial name
- NCT02141087
- Testing
- Pirfenidone
- Sponsor
- Genentech, Inc.
Idiopathic Pulmonary Fibrosis
A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising…
- Trial name
- NCT06081621
- Testing
- REGEND001
- Where
- 4 sites in China
- Volunteers
- 23 people
- Sponsor
- Regend Therapeutics
Lung Diseases, Interstitial
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
This study in China is open to people with progressive lung fibrosis (chronic fibrosing ILDs with progressive phenotype) who are at least 18 years old.
- Trial name
- NCT05065190
- Testing
- Nintedanib
- Where
- 16 sites in China
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions
A Randomized, Open-Label, Two-Period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Chinese Subjects under Fed Conditions Primary objective…
- Trial name
- NCT06588517
- Testing
- Pirfenidone Modified-Release Tablets, Pirfenidone Tablets
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Lung Diseases, Interstitial
An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite…
- Trial name
- NCT03843892
- Testing
- OFEV
- Where
- 6 sites in United States
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT06003426
- Testing
- BMS-986278
- Where
- 390 sites in United States, Argentina and 31 more
- Volunteers
- 1,255 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
The primary purpose of the study is to evaluate the safety and PK profile of CC-930 in idiopathic pulmonary fibrosis patients.
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Fibrosis, Interstitial Lung Disease
- Trial name
- NCT01203943
- Testing
- CC-930
- Where
- 22 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- Celgene
Idiopathic Pulmonary Fibrosis
Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
This is a multi-center, non-interventional study to assess and describe course and outcomes in patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) who are treated with Esbriet (pirfenidone) in Canada, by measuring and…
- Trial name
- NCT02552849
- Testing
- No intervention
- Where
- 26 sites in Canada
- Volunteers
- 305 people
- Sponsor
- Hoffmann-La Roche